51 related articles for article (PubMed ID: 34685632)
1. USP28: Oncogene or Tumor Suppressor? A Unifying Paradigm for Squamous Cell Carcinoma.
Prieto-Garcia C; Tomašković I; Shah VJ; Dikic I; Diefenbacher M
Cells; 2021 Oct; 10(10):. PubMed ID: 34685632
[TBL] [Abstract][Full Text] [Related]
2. Maintaining protein stability of ∆Np63 via USP28 is required by squamous cancer cells.
Prieto-Garcia C; Hartmann O; Reissland M; Braun F; Fischer T; Walz S; Schülein-Völk C; Eilers U; Ade CP; Calzado MA; Orian A; Maric HM; Münch C; Rosenfeldt M; Eilers M; Diefenbacher ME
EMBO Mol Med; 2020 Apr; 12(4):e11101. PubMed ID: 32128997
[TBL] [Abstract][Full Text] [Related]
3. The dimeric deubiquitinase USP28 integrates 53BP1 and MYC functions to limit DNA damage.
Jin C; Einig E; Xu W; Kollampally RB; Schlosser A; Flentje M; Popov N
Nucleic Acids Res; 2024 Apr; 52(6):3011-3030. PubMed ID: 38227944
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for the bi-specificity of USP25 and USP28 inhibitors.
Patzke JV; Sauer F; Nair RK; Endres E; Proschak E; Hernandez-Olmos V; Sotriffer C; Kisker C
EMBO Rep; 2024 May; ():. PubMed ID: 38816515
[TBL] [Abstract][Full Text] [Related]
5. Preclinical testing of CT1113, a novel USP28 inhibitor, for the treatment of T-cell acute lymphoblastic leukaemia.
Xu J; Peng J; Sun S; Wang D; Yuan W; Yang X; Shi T; Wang R; Liu H; Zhang P; Zhu HH
Br J Haematol; 2024 Apr; ():. PubMed ID: 38685813
[TBL] [Abstract][Full Text] [Related]
6. The landscape of driver mutations in cutaneous squamous cell carcinoma.
Chang D; Shain AH
NPJ Genom Med; 2021 Jul; 6(1):61. PubMed ID: 34272401
[TBL] [Abstract][Full Text] [Related]
7. Ubiquitin-specific protease 28: the decipherment of its dual roles in cancer development.
Ren X; Jiang M; Ding P; Zhang X; Zhou X; Shen J; Liu D; Yan X; Ma Z
Exp Hematol Oncol; 2023 Mar; 12(1):27. PubMed ID: 36879346
[TBL] [Abstract][Full Text] [Related]
8. Tumor Suppressor FBXW7 and Its Regulation of DNA Damage Response and Repair.
Lan H; Sun Y
Front Cell Dev Biol; 2021; 9():751574. PubMed ID: 34760892
[TBL] [Abstract][Full Text] [Related]
9. Exosome-transported circ_0061407 and circ_0008103 play a tumour-repressive role and show diagnostic value in non-small-cell lung cancer.
Chen Z; Ma X; Chen Z; Chen W; Li L; Lin Y; Hu Y; Shang Y; Zhao Y; He J; Zhou C; Meng X
J Transl Med; 2024 May; 22(1):427. PubMed ID: 38711144
[TBL] [Abstract][Full Text] [Related]
10. Protein Stability Regulation in Osteosarcoma: The Ubiquitin-like Modifications and Glycosylation as Mediators of Tumor Growth and as Targets for Therapy.
Di Gregorio J; Di Giuseppe L; Terreri S; Rossi M; Battafarano G; Pagliarosi O; Flati V; Del Fattore A
Cells; 2024 Mar; 13(6):. PubMed ID: 38534381
[TBL] [Abstract][Full Text] [Related]
11. USP28 promotes tumorigenesis and cisplatin resistance by deubiquitinating MAST1 protein in cancer cells.
Karapurkar JK; Colaco JC; Suresh B; Tyagi A; Woo SH; Jo WJ; Ko N; Singh V; Hong SH; Oh SJ; Kim KS; Ramakrishna S
Cell Mol Life Sci; 2024 Mar; 81(1):145. PubMed ID: 38498222
[TBL] [Abstract][Full Text] [Related]
12. The deubiquitinase USP28 maintains the expression of the transcription factor MYCN and is essential in neuroblastoma cells.
Li J; Peng J; Wu L; Shen X; Zhen X; Zhang Y; Ma H; Xu Y; Xiong Q; Zhu Q; Zhang P
J Biol Chem; 2023 Jul; 299(7):104856. PubMed ID: 37230388
[TBL] [Abstract][Full Text] [Related]
13. USP28 controls SREBP2 and the mevalonate pathway to drive tumour growth in squamous cancer.
Maier CR; Hartmann O; Prieto-Garcia C; Al-Shami KM; Schlicker L; Vogel FCE; Haid S; Klann K; Buck V; Münch C; Schmitz W; Einig E; Krenz B; Calzado MA; Eilers M; Popov N; Rosenfeldt MT; Diefenbacher ME; Schulze A
Cell Death Differ; 2023 Jul; 30(7):1710-1725. PubMed ID: 37202505
[TBL] [Abstract][Full Text] [Related]
14. Prevalence, causes and impact of TP53-loss phenocopying events in human tumors.
Fito-Lopez B; Salvadores M; Alvarez MM; Supek F
BMC Biol; 2023 Apr; 21(1):92. PubMed ID: 37095494
[TBL] [Abstract][Full Text] [Related]
15. The Role of Deubiquitinating Enzyme in Head and Neck Squamous Cell Carcinoma.
Jin S; Kudo Y; Horiguchi T
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613989
[TBL] [Abstract][Full Text] [Related]
16. Research Progress for Targeting Deubiquitinases in Gastric Cancers.
An T; Lu Y; Gong Z; Wang Y; Su C; Tang G; Hou J
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497313
[TBL] [Abstract][Full Text] [Related]
17. MAPK Signaling Pathway in Oral Squamous Cell Carcinoma: Biological Function and Targeted Therapy.
Cheng Y; Chen J; Shi Y; Fang X; Tang Z
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230547
[TBL] [Abstract][Full Text] [Related]
18. USP28 enables oncogenic transformation of respiratory cells, and its inhibition potentiates molecular therapy targeting mutant EGFR, BRAF and PI3K.
Prieto-Garcia C; Hartmann O; Reissland M; Braun F; Bozkurt S; Pahor N; Fuss C; Schirbel A; Schülein-Völk C; Buchberger A; Calzado Canale MA; Rosenfeldt M; Dikic I; Münch C; Diefenbacher ME
Mol Oncol; 2022 Sep; 16(17):3082-3106. PubMed ID: 35364627
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
